Clinical trial
Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis
NCT00348296 · Benesis Corporation, Industry · Completed
Key facts
| NCT number | NCT00348296 |
|---|---|
| Title | Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis |
| Official title | A Randomized, Double-blind, Placebo-controlled Multi-center Study of GB-0998 for Treatment of Systemic Sclerosis |
| Lead sponsor | Benesis Corporation, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Scleroderma, Systemic |
| Intervention type | Drug |
| Interventions | High-dose intravenous immunoglobulin (Venoglobulin-IH) |
| Enrollment | 60 |
| Start date | Jul 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Jul 4, 2006 |
| Last update posted | Jul 30, 2010 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: